- 1Clinical Medicine, Division of Gastroenterology and Hepatology, University of Miami, Miami, FL, USA.
- 2Division of Gastroenterology and Hepatology, Mayo Clinic. Scottsdale, AZ. Office of University Provost, Arizona State University, Phoenix, AZ, USA.
- 3Division of Gastroenterology and Hepatology, University of Miami, Miami, FL, USA.
Background and aim: Off-label use of fibrates in patients with cholestatic liver diseases results in improved biochemical parameters and pruritus; however, their safety in this population has been a concern. This study summarizes safety data for fibrates when used for treatment of cholestatic liver diseases.
Methods: A systematic review of published studies evaluating the use of fibrates for treatment of primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) was performed. Electronic databases were searched up to December 2019 for published studies evaluating treatment outcomes associated to fibrates for these two diseases.
Results: A total of 37 studies were identified, including 31 for PBC and 6 for PSC, with a total of 1107 unique patients treated with fibrates ± ursodeoxycholic acid (UDCA). Most studies evaluated fenofibrate and bezafibrate, and only one study evaluated pemafibrate. There were no studies evaluating gemfibrozil or clofibrate. The most commonly reported adverse events (AEs) were gastrointestinal and musculoskeletal. Elevations of aminotransferases and serum creatinine were reported more commonly in patients treated with ursodeoxycholic acid (UDCA) plus Fibrates versus UDCA monotherapy.
Conclusions: fibrates appear to be safe and well tolerated in patients with PBC, with a low frequency of AEs. There are scarce data about the safety of these agents for treatment of PSC.